Boston, Massachusetts-based non-profit The Institute for Clinical and Economic Review (ICER) has issued its final report into the cost-effectiveness of the latest generation of weight loss treatments.
The group has been comparing the comparative clinical effectiveness and value of Novo Nordisk’s (NOVO: N) Wegovy (semaglutide) and Saxenda (liraglutide), as well as Qsymia (phentermine/topiramate), from Vivus Pharmaceuticals (Nasdaq: VVUS), and Contrave (bupropion/naltrexone), from Currax Pharma.
Wegovy in particular has attracted a lot of interest and excitement, with evidence showing a dramatic impact on weight loss.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze